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1 Commentary
The prevalence, socioeconomic and clinical burden of
chronic heart failure with reduced left ventricular (LV)
ejection fraction (HFrEF) is exponentially growing [1].
Ventricular tachycardia (VT) frequently occurs in patients
with HFrEF, and is not only a phenotype of structural heart
disease [2] but may indicate progression of heart failure and
risk of decompensation. VT ablation serves as a symptomatic and prognostic therapy in affected patients and has a
Class IIa recommendation (level of evidence B) in the European Society of Cardiology guidelines [3]. VT ablation often
requires prolonged procedural times, prolonged duration in
VT, repetitive endocardial stimulation, and may result in
acute hemodynamic decompensation (AHD). The PAINESD
score serves as an important predictor of AHD [4] and can
help to decide if pre-emptive hemodynamic support is warranted. Although there is encouraging retrospective data on
hemodynamic support [5, 6], randomized controlled trials
on the utilization of percutaneous ventricular assist devices
(pVAD) for VT ablation are lacking, and there is wide variation of use. In this context, we read the study of Chen et al.
with great interest [7], yet the conclusions drawn from the
results raise several concerns.
The authors analyze a cohort of 69 patients who underwent VT ablation supported with an Impella 2.5 or CP pVAD
(Abiomed, Danvers, MA, USA), chosen at the operator’s
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discretion). The cohort was divided into two groups based
upon on duration of support. The early cohort (43 patients)
included those who had pVAD removed within 24 h of ablation, and the delayed cohort (26 patients) included those who
required pVAD for > 24 h (up to 9 days). Within the delayed
cohort, 12 of 26 patients had a change to “other” hemodynamic support devices, while 14 remained on Impella alone.
Mortality in the delayed cohort (50.0%) was significantly
higher than in the early cohort (2.3%), leading the authors to
entitle their manuscript and conclude that “delayed removal
is associated with increased mortality.”
A few points to consider:
(1) pVAD was employed “per operator discretion;” however, there is no information provided what criteria,
if any, were used for employing pVAD support and
choosing between devices.
(2) The level of shock and hemodynamics prior to the procedure were not reported. Given the heterogeneity of
such patients this information is needed. Patients may
present with VT storm and cardiogenic shock, or stable
HFrEF tolerating medical therapy in a rather elective
setting. In fact, the delayed cohort had twice as many
patients presenting in VT storm and this difference
alone may account for the results of this study.
(3) It is not clear if use of pVAD was performed preemptively or as a rescue. This is important because emergent use of pVAD has been shown to be associated with
worse outcomes [5, 8, 9].
(4) The authors mention that the most prevalent cause of
death was progressive shock or refractory HF. It is
unclear why 9 patients were switched from Impella to
IABP, which provides less support. Similarly of the
13 patients who died, it is unclear why no patient was
escalated to ECMO along with the Impella already in
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place (ECPELLA), which provides robust hemodynamic support.
(5) Providing additional information on number and duration of antiarrhythmic medications would be useful,
and if prior VT ablation had been performed.
(6) It would further be useful to know how patients were
sedated, as the use of general anesthesia poses a risk
of deterioration and shock for patients with HFrEF, as
well as when patients were extubated? General anesthesia for the whole period of support in the delayed
cohort would in part explain the worse outcome.
(7) Lastly, it would be important to know how patients
were weaned from pVAD and if invasive hemodynamics were used. Though the authors mention possible
harm with the use of pulmonary artery (PA) catheters,
the studies referenced are still controversial and did
not include patients with pVAD or patients in cardiogenic shock. In fact, the use of PA catheters has been
recently associated with improved outcomes in patients
with cardiogenic shock [10, 11]. Unlike percutaneous
coronary interventions which predominantly affect the
LV, repeated VT will affect both LV and RV function.
Therefore, a complete understanding of biventricular
function is important in this context and will facilitate
early detection of hemodynamic decompensation.
The cohorts differ in several aspects: patients in the delayed
cohort had a numerically lower LVEF, more COPD, more
chronic kidney disease, more diabetes, higher NYHA class,
and a higher PAINESD score. Even if not statistically significant, due to the sample size, the delayed cohort is substantially
sicker. These factors contribute to a higher risk and higher
heart failure severity of this cohort of patients, which presumably resulted in the longer duration of hemodynamic support.
This is also reflected by the four times higher proportion of
Impella CP use in the delayed cohort, as treating physicians
likely considered these patients to require a higher level of
support. Finally, the delayed cohort underwent longer procedures, longer durations on VT, and more ventricular fibrillation
induction. Therefore, in the presence of already higher preexisting morbidity, patients underwent more stressful procedures,
resulting in the need for longer duration of hemodynamic support. The investigators could consider adjusting for the aforementioned baseline differences or performing a matched pair
analysis. Notwithstanding, a prospective study is needed to test
outcome effects of prolonged versus limited time on support,
in cohorts with comparable pre-existing risk and morbidity.
The mean LVEF in the early and delayed cohorts was 27.1
and 20.6%, respectively; however, many patients were not on
optimal medical therapy for heart failure: Only 50 to 60%
had an ACEI/ARB, and the use of mineralocorticoid receptor antagonists and sacubitril/valsartan was not reported.
Higher intensity medical therapy before the procedure may
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have resulted in better procedural outcomes. Patients who
were not able to tolerate medical therapy, or who had VT
storm with poor LV function, might have had refractory
end stage heart failure. This would warrant evaluation for
advanced heart failure therapies such as durable LVAD or
cardiac transplantation, rather than high-risk VT ablation.
Randomized controlled trials on the use of pVAD in
interventional or electrophysiological procedures are difficult to conduct. Reporting data from observational studies is therefore essential; however, inherent forms of bias
must be considered. Concluding that prolonged support per
se is the cause of higher mortality is not well supported
by the evidence presented. It is not the time on support,
but the underlying severity of heart failure, the existence
of comorbidities, and the hemodynamic deterioration of a
prolonged and complex procedure which drives morbidity
and mortality. Careful patient selection and timing, use of
multi-modality heart teams, use of invasive hemodynamics for decision making and monitoring, and individualized
mechanical circulatory support strategies are crucial in our
efforts to maximize patient outcomes.
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